CAR-T, Monoclonal Antibodies, and ADCs Revolutionize the CD Antigen Cancer Therapy Market | Top Companies are Seattle Genetics Inc, АrуоGеn Віорhаrmа, Віосаd

The CD Antigen Cancer Therapy Market is valued at at a significant CAGR during the forecast period (2024-2031).

CD Antigen Cancer Therapy involves monoclonal antibodies or CAR-T therapies targeting specific cluster of differentiation (CD) antigens on cancer cells. Growth is driven by immunotherapy adoption, oncology R&D, and precision medicine trends. Therapies enhance efficacy while reducing off-target effects. Hospitals, cancer centers, and biotech companies are key end-users. Clinical trials and FDA approvals fuel innovation. Advances in CAR-T, bispecific antibodies, and combination therapies expand treatment options. Rising cancer prevalence globally supports market growth.

📌 Download Sample Report to Identify Emerging Deals & Opportunities in the CD Antigen Cancer Therapy Market Landscape:- https://datamintelligence.com/download-sample/cd-antigen-cancer-therapy-market?Ranjith

☛ CD Antigen Cancer Therapy Market Recent Developments 2025:

United States: Recent Industry Developments

✅ In August 2025, Gilead Sciences announced promising Phase 3 trial results for its CD47-targeting antibody therapy, showing improved survival in patients with advanced hematologic malignancies.

✅ In July 2025, Bristol Myers Squibb (BMS) launched a new CD19-directed CAR-T cell therapy for relapsed B-cell lymphoma, strengthening its oncology portfolio in the U.S. market.

✅ In June 2025, Pfizer initiated clinical studies on a bispecific antibody targeting CD20 and CD3, enabling T-cell redirection and enhanced cytotoxicity against resistant B-cell cancers.

Europe: Recent Industry Developments

✅ In August 2025, Roche received EMA approval for its CD20xCD3 bispecific antibody, marketed for the treatment of follicular lymphoma, expanding its leadership in hematologic oncology.

✅ In July 2025, Novartis advanced its CD22-targeted antibody-drug conjugate (ADC) program into Phase 2 clinical trials, demonstrating strong tumor-specific binding and reduced systemic toxicity.

✅ In June 2025, AstraZeneca entered a research collaboration with Oxford Biotherapeutics to develop CD205-targeted immunotherapies, aiming to expand its precision oncology pipeline.

Japan: Recent Industry Developments

✅ In August 2025, Takeda Pharmaceutical announced preclinical success of its CD38 monoclonal antibody for multiple myeloma, with plans to enter Phase 1 trials by early 2026.

✅ In July 2025, Chugai Pharmaceutical (a Roche subsidiary) initiated a Phase 2 trial for its CD137 agonist antibody, focusing on solid tumor immunotherapy in combination with checkpoint inhibitors.

✅ In June 2025, Daiichi Sankyo expanded its ADC platform with a CD123-targeting conjugate, aiming to address unmet needs in acute myeloid leukemia (AML) treatment.

☛ CD Antigen Cancer Therapy Market Competitive Landscape:

Seattle Genetics Inc, АrуоGеn Віорhаrmа, Віосаd, Віоgеn Іdес, Сеlltrіоn, Gеnеntесh, Gеnmаb, Merck, Sandoz, Eli Lilly the Company.

Research Methodology

We follow a hybrid research approach, combining qualitative insights with rigorous quantitative analysis to deliver reliable and comprehensive market intelligence. Our process begins with extensive secondary research, drawing on trusted industry reports, proprietary databases, and credible market sources. This is then reinforced through targeted primary research, including structured surveys and in-depth interviews with industry leaders, subject matter experts, and key market participants.

📌 Request a Customized Market Report - Tailored insights to match your business goals: https://datamintelligence.com/customize/cd-antigen-cancer-therapy-market?Ranjith

☛ Segments Covered in the CD Antigen Cancer Therapy Market:

By Product Type: Monoclonal Antibodies, Antibody-drug conjugates, CAR-T Cell Therapies, Тrі-Funсtіоnаl аnd Ві-Ѕресіfіс Т-Сеll Еngаgеr Аntіbоdіеѕ, Others.

By Type: CD19, CD20, CD22, CD30, Others.

By Therapy Type: Targeted Therapy, Immunotherapy, Combination Therapy, Monotherapy, Others.

By End-User: Hospitals, Cancer research centers, Clinics, Others.

☛ This Report Includes:

✔ Comprehensive go-to-market strategies with actionable insights.

✔ Unbiased evaluation of overall market performance.

✔ Deep-dive analysis into development trends, competitive landscape, supply-demand dynamics, YoY growth, benchmarking, vendor mapping, market access, and overall progress.

✔ Tailored regional and country-level reports with detailed localized analysis available on request.

✔ Identification of niche segments and high-growth regions presenting strong opportunities.

✔ Accurate regional forecasts using both top-down and bottom-up approaches.

📌 Get Corporate Access to Live CD Antigen Cancer Therapy Industry Intelligence Database: https://www.datamintelligence.com/buy-now-page?report=cd-antigen-cancer-therapy-market?Ranjith

☛ Regional Analysis for CD Antigen Cancer Therapy Market:

⇥ North America (U.S., Canada, Mexico)

⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

⇥ South America (Colombia, Brazil, Argentina, Rest of South America)

⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

📌 Request for 2 Days FREE Trial Access: https://www.datamintelligence.com/reports-subscription

☛ Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

✅ Competitive Landscape
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Unmet Needs & Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Quarterly Industry Report Updated
✅ Live Market & Pricing Trends
✅ Import-Export Data Monitoring

☛ Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.